Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.
Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K. Sasada S, et al. Among authors: kinoshita t. Ann Oncol. 2017 Aug 1;28(8):2028-2029. doi: 10.1093/annonc/mdx227. Ann Oncol. 2017. PMID: 28505219 Free article. No abstract available.
64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer.
Tamura K, Kurihara H, Yonemori K, Tsuda H, Suzuki J, Kono Y, Honda N, Kodaira M, Yamamoto H, Yunokawa M, Shimizu C, Hasegawa K, Kanayama Y, Nozaki S, Kinoshita T, Wada Y, Tazawa S, Takahashi K, Watanabe Y, Fujiwara Y. Tamura K, et al. Among authors: kinoshita t. J Nucl Med. 2013 Nov;54(11):1869-75. doi: 10.2967/jnumed.112.118612. Epub 2013 Sep 12. J Nucl Med. 2013. PMID: 24029656 Free article.
Visualization of HER2-specific breast cancer intratumoral heterogeneity using 64Cu-DOTA-trastuzumab PET.
Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K. Sasada S, et al. Among authors: kinoshita t. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2146-2147. doi: 10.1007/s00259-017-3781-6. Epub 2017 Aug 3. Eur J Nucl Med Mol Imaging. 2017. PMID: 28770275 No abstract available.
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer.
Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y. Tamura K, et al. Among authors: kinoshita t. Ann Oncol. 2011 Jun;22(6):1302-1307. doi: 10.1093/annonc/mdq585. Epub 2010 Nov 25. Ann Oncol. 2011. PMID: 21109570 Free article. Clinical Trial.
Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy.
Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, Ono M, Kouno T, Ando M, Tamura K, Katsumata N, Hasegawa T, Kinoshita T, Fujiwara Y. Yonemori K, et al. Among authors: kinoshita t. Med Oncol. 2009;26(3):344-9. doi: 10.1007/s12032-008-9127-2. Epub 2008 Nov 18. Med Oncol. 2009. PMID: 19016009
A case of ductal carcinoma in situ of the breast.
Yoshida M, Kinoshita T. Yoshida M, et al. Among authors: kinoshita t. Jpn J Clin Oncol. 2009 Feb;39(2):132. doi: 10.1093/jjco/hyn152. Jpn J Clin Oncol. 2009. PMID: 19155284 No abstract available.
TERT promoter hotspot mutations in breast cancer.
Shimoi T, Yoshida M, Kitamura Y, Yoshino T, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Ichimura K, Fukuda T, Fujiwara Y, Tamura K. Shimoi T, et al. Among authors: kinoshita t. Breast Cancer. 2018 May;25(3):292-296. doi: 10.1007/s12282-017-0825-5. Epub 2017 Dec 8. Breast Cancer. 2018. PMID: 29222734 Free PMC article.
3,551 results